PDF(Pubmed)
Abstract：
Although previous studies have shown no increased mortality risk after the primary series of COVID-19 mRNA vaccines, reports on booster doses are lacking. This study aimed to evaluate mortality risk after the mRNA vaccine boosters in addition to the primary series. This nested case-control study included two age-specific cohorts (18-64 and ≥65 years as of February 1, 2021) in two municipalities. All deaths were identified and matched five controls for each case at each date of death (index date) with risk set sampling according to municipality, age, and sex. The adjusted odds ratios (aORs) and 95% confidence intervals (CIs) for mRNA vaccines (first to fifth doses) were estimated by comparing with no vaccination within 21 and 42 days before the index date using a conditional logistic regression model. The 18-64-years cohort comprised 431 cases (mean age, 57.0 years; men, 58.2%) and 2,155 controls (mean age, 56.0; men, 58.2%), whereas the ≥65-years cohort comprised 12,166 cases (84.0; 50.2%) and 60,830 controls (84.0, 50.2%). The aORs (95% CI) in 0-21 days after the third and fourth doses in the 18-64-years cohort were 0.62 (0.24, 1.62) and 0.38 (0.08, 1.84), respectively. The aORs (95% CI) after the third to fifth doses in the ≥65 years cohort were 0.36 (0.31, 0.43), 0.30 (0.25, 0.37), and 0.26 (0.20, 0.33), respectively. In conclusion, booster doses of mRNA vaccines do not increase mortality risk. These findings could help subsequent vaccine campaigns and alleviate vaccine hesitancy.
摘要：
尽管之前的研究表明，在主要系列COVID-19mRNA疫苗接种后，死亡风险没有增加，缺乏关于加强剂量的报告。这项研究旨在评估除主要系列外的mRNA疫苗增强剂之后的死亡风险。这项嵌套病例对照研究包括两个城市的两个年龄特定队列（截至2021年2月1日18-64岁和≥65岁）。确定所有死亡病例，并在每个死亡日期（索引日期）对每个病例进行5个对照，并根据市政当局进行风险集抽样，年龄,和性爱。mRNA疫苗（第一至第五剂量）的调整比值比（aOR）和95％置信区间（CIs）是通过使用条件逻辑回归模型在指标日期前21和42天内与未接种疫苗进行比较来估计的。18-64岁的队列包括431例(平均年龄，57.0岁；男人，58.2%)和2,155名对照(平均年龄，56.0；男子，58.2%)，而≥65年队列包括12,166例(84.0;50.2%)和60,830例对照(84.0,50.2%)。在18-64年队列中，第三次和第四次给药后0-21天的aOR（95％CI）分别为0.62（0.24，1.62）和0.38（0.08，1.84），分别。≥65年队列中第三至第五剂量后的aOR（95％CI）为0.36（0.31，0.43），0.30（0.25，0.37），和0.26（0.20，0.33），分别。总之,mRNA疫苗的加强剂量不会增加死亡风险.这些发现可以帮助后续的疫苗运动和缓解疫苗的犹豫。
